Compass Pathways' latest update reveals extended trial timelines, staff cuts, and financial concerns, raising questions about ...

In its presentation at ObesityWeek 2024 meeting in Texas, the multinational drug company AstraZeneca (NASDAQ:AZN) revealed ...

Biopharmaceutical company Angitia Biopharmaceuticals has begun a Phase II clinical trial of AGA2118, a bispecific antibody designed for treating osteoporosis. The first patient has been dosed in the ...

The initial trio of patients with glioblastoma have begun treatment with ropidoxuridine in a phase 2 clinical trial, ...

This study sought to assess predictors of financial toxicity in early-phase clinical trial participants. Age, education level, and income are significant predictors of financial toxicity in patients ...

Bright Minds Biosciences' BMB-101 shows promise in treating drug-resistant epilepsy. Read why DRUG stock is a strong ...

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...

A first healthy adults group has been dosed in an early clinical trial of an oral and myelin-protective treatment for all types of MS.

Recce Pharmaceuticals is nearing completion in its Phase II clinical trial for acute bacterial skin and skin structure ...

Ventus Therapeutics, a clinical-stage biopharmaceutical company utilizing its proprietary ReSOLVE™ platform to discover and ...

On November 1, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as 'Chipscreen Biosciences') and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceutical Ltd., received the ...

PAR made substantial progress in its Phase 3 clinical trial preparations for the treatment of knee osteoarthritis (OA) with ...